Edition:
United Kingdom

Adverum Biotechnologies Provides Clinical Program Update On Advm-022 Gene Therapy For Wet AMD


Monday, 15 Apr 2019 

April 15 (Reuters) - Adverum Biotechnologies Inc ::ADVERUM BIOTECHNOLOGIES PROVIDES CLINICAL PROGRAM UPDATE ON ADVM-022 GENE THERAPY FOR WET AMD.ADVERUM BIOTECHNOLOGIES INC - CLINICAL HOLD UNTIL ADDITIONAL CMC INFORMATION IS REVIEWED BY FDA.ADVERUM BIOTECHNOLOGIES INC - INDEPENDENT DMC REVIEW OF SAFETY DATA FROM FIRST COHORT OF SIX PATIENTS WITH NO SAES OR DLTS.ADVERUM BIOTECHNOLOGIES INC - ADVERUM PLANS TO PRESENT 24-WEEK DATA FROM FIRST COHORT OF PATIENTS AT SCIENTIFIC MEETING IN 2H19.ADVERUM BIOTECHNOLOGIES - INDEPENDENT DATA MONITORING COMMITTEE (DMC) DETERMINED THAT ENROLLMENT AND DOSING OF PATIENTS IN SECOND COHORT COULD PROCEED.ADVERUM - RECEIVED NOTIFICATION FROM FDA IN EARLY APRIL REQUESTING ADDITIONAL CMC INFORMATION AND REQUIREMENTS ON ADVM-022 MANUFACTURING PROCESS.ADVERUM BIOTECHNOLOGIES INC - FDA HAS PLACED COMPANY'S IND ON CLINICAL HOLD UNTIL AGENCY HAS REVIEWED ADVERUM'S RESPONSE. 

Company Quote

9.22
0.05 +0.55%
24 May 2019